- Home
- ACIC vs MLYS Comparison
ACIC vs MLYS Comparison
Compare ACIC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | MLYS |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | 68 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.1M | 2.4B |
| IPO Year | 2007 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ACIC | MLYS |
|---|---|---|
| Price | $11.39 | $23.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $48.67 |
| AVG Volume (30 Days) | 244.0K | ★ 1.1M |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | ★ 6.78% | N/A |
| EPS Growth | ★ 39.61 | 37.43 |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.00 | N/A |
| P/E Ratio | $5.15 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.97 | $10.44 |
| 52 Week High | $13.06 | $47.65 |
Technical Indicators
Market Signals| Indicator | ACIC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 30.97 |
| Support Level | $10.97 | $13.42 |
| Resistance Level | $11.85 | $31.09 |
| Average True Range (ATR) | 0.27 | 1.75 |
| MACD | -0.02 | -0.27 |
| Stochastic Oscillator | 56.34 | 10.05 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.